Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Status Completed

Clinical Trial Summary

The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients

Clinical Trial Description

Direct-acting antivirals (DAAs) combination therapies from various mechanisms of action and families have been revolutionized the management landscape of chronic hepatitis C virus (HCV). Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) are approved to treat HCV genotype 4 (GT4) infection. Here, investigators' objective was to delineate the efficacy and safety of OBV/PTV/r plus RBV of HCV GT4 in the treatment of Egyptian naïve patients.

Between 5 January and 8 September 2017, a cohort of 100 Egyptian patients infected with HCV GT4 was allocated and administered orally OBV/PTV/r with RBV, for 12 weeks, which given as oral tablets based on patient tolerability. The primary endpoint of investigators' study was a sustained virological response (HCV RNA < 12 IU/mL) 12 weeks from the cessation of the treatment (SVR12). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04378608
Study type	Interventional
Source	Beni-Suef University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	January 5, 2017
Completion date	September 8, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02487030` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection	Phase 3
Active, not recruiting	`NCT05460130` - Implementing HCV Treatment for High-risk Populations in Austin, Texas	N/A
Completed	`NCT02220998` - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection	Phase 3
Terminated	`NCT01052090` - Safety and Efficacy Study in Hepatitis C Patients With PHN121	Phase 1/Phase 2
Completed	`NCT02537379` - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection	N/A
Recruiting	`NCT04156945` - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men	N/A
Terminated	`NCT02510300` - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn	`NCT04309734` - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects	Phase 1/Phase 2
Active, not recruiting	`NCT04001608` - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients	Phase 3
Completed	`NCT04112303` - Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis	Phase 3
Completed	`NCT02251717` - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection	Phase 2
Recruiting	`NCT05092074` - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting	`NCT04005248` - Prevalence of HCV in HIV-negative MSM	N/A
Completed	`NCT02249182` - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection	Phase 2
Completed	`NCT02939989` - Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study	Phase 3
Completed	`NCT01718145` - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects	Phase 3
Completed	`NCT01482611` - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382	Phase 1
Completed	`NCT00255177` - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	Phase 2
Terminated	`NCT02600351` - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies	Phase 3
Completed	`NCT04980157` - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers